Predictive Performance of the TRI-SCORE in Patients with Severe Aortic Stenosis and Concomitant Tricuspid Regurgitation Undergoing TAVR

M. Mousa Basha (Bonn)1
1Universitätsklinikum Bonn Medizinische Klinik und Poliklinik II Bonn, Deutschland
Background
Transcatheter aortic valve implantation (TAVR) has established as the treatment of choice for high-risk patients with severe aortic stenosis (AS). Tricuspid regurgitation (TR) is often linked to AS and consecutive left-sided heart failure and is associated with adverse outcomes. Risk stratification through clinical scoring systems is vital for guiding therapeutic decisions.

Objectives
To assess the applicability of the TRI-SCORE for predicting adverse outcomes in patients with AS and concomitant moderate-to-severe TR undergoing TAVR and to compare its performance with established surgical rusk scores like the EuroSCORE II and Society of Thoracic Surgeons (STS) score.

Methods
We conducted a retrospective analysis of 310 patients with severe AS and concomitant TR who underwent TAVR between 2013 and 2022 at the Heart Center Bonn. According to the TRI-SCORE, patients were stratified into a low or intermediate risk group (TRI-SCORE 0–5) and a high-risk group (TRI-SCORE 6–12). The primary endpoint was 2-year all-cause mortality. Predictive values of the TRI-SCORE were compared to the EuroSCORE II and the STS scores for both 30-day and 2-year mortality outcomes.

Results
The 2-year mortality rate was significantly higher in the high-risk group compared to the low or intermediate-risk group (38.4% vs. 17.7%; p < 0.001). For predicting 30-day mortality, the EuroSCORE II and the STS score demonstrated superior predictive values, with AUCs of 78.4% and 81.7%, respectively, in comparison to the TRI-SCORE, which showed an AUC of 70.6%. Conversely, the TRI-SCORE allowed a better risk prediction with regard to the 2-year all-cause mortality, achieving an AUC of 70.6%, superior to the EuroSCORE II (61.3%) and the STS Score (60.1%).

Conclusion
The TRI-SCORE is effective in predicting mid-term mortality in patients with AS and moderate-to-severe TR undergoing TAVR, demonstrating greater robustness than the EuroSCORE II and the STS score for this timeframe. While the AUC for the TRI-SCORE is acceptable, further refinement is necessary to enhance its predictive capabilities.